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COMPARING THE EFFICACY AND SAFETY OF POTENTIAL CLINICAL 
VACCINES FOR THE EBOLA VIRUS 
JASON KIM 
 
ABSTRACT 
 
 The Ebola virus disease is one of the most dangerous diseases to develop into a 
major health concern in the modern era, largely because of the ZEBOV outbreak that has 
devastated West Africa from 2014 to 2016. The outbreak has compelled many countries 
and organizations to prioritize finding a vaccine for Ebola, which is key to preventing a 
similar outbreak on a global scale. As a result, studies on Ebola vaccines have increased 
in frequency since 2014. This thesis will focus on three vaccine candidates that could 
potentially be developed into a future vaccine for Ebola: chAd3, rVSV, and rAd5. Each 
of the vaccines has been the focus of several studies on both animals and humans, which 
have provided information and understanding of the vaccines’ characteristics in terms of 
reactogenicity and immunogenicity. All of the vaccines demonstrate safety and 
immunogenicity profiles that offer promise for the vaccines as future candidates, which at 
first makes them seem very similar to each other. However, they each differ substantially 
in their flaws and ability to generate an immunogenic response. More specifically, the 
chAd3 vaccine requires a boost of MVA to reach its full potential, the rVSV vaccine has 
expressed a higher level of reactogenicity and adverse effects than the other two vaccines, 
and the rAd5 vaccine’s efficacy is weakened by the presence of pre-existing immunity 
against Ad5 in the human population. 
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INTRODUCTION 
 Few diseases have demanded as much of the world’s attention in the modern era 
as much as Ebola. Although Ebola outbreaks had previously occurred before the year 
2000, the disease became an international health concern when an outbreak of the Zaire 
species broke out in Sierra Leone, Guinea, and Liberia from 2014-2016 (WHO, 2017). 
The outbreak devastated the area of West Africa both in terms of lives lost and 
socioeconomically, prompting several countries to prioritize finding a vaccine to Ebola in 
order to weaken the spread of Ebola and to prevent the disease from uncontrollably 
expanding into a worldwide health crisis. Several vaccine candidates have been studied 
by scientists, all of whom share the common goal of finding the most effective vaccine 
for Ebola. Three candidates have stood out as potential solutions to this unmet need: 
Chimpanzee Adenovirus Type 3, recombinant Vesicular Stomatitis Virus, and 
Recombinant Adenovirus Type 5. The three vaccines, despite their differences in origin 
and characteristics, are actually very similar in their underlying premise. They are each 
viral vaccine vectors that express GP, a surface protein that is found on the Ebola virus. 
 
Vaccine Immunogenicity 
One of the most important characteristics of a potential vaccine’s viability is its 
ability to generate an immunogenic response. The presence of GP can elicit an immune 
response through the presence of anti-GP specific antibodies, which are measured mainly 
by ELISA and are one of the primary measures of a vaccine’s ability to induce an 
immune response. The T-cell response is a secondary measure through which a vaccine’s 
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immunogenicity is analyzed, and is commonly studied using ELISPOT. Anti-GP specific 
antibodies and T-cell responses can be used to measure a vaccine’s ability to provide both 
short-term (within about a month after vaccination) and long-term protection (which is 
generally analyzed around 6 months after vaccination). Because most of the studies on 
vaccines do not directly test the effectiveness of a vaccine against Ebola, the strength, 
frequency, and durability of the antibody or T-cell responses is the main indicator of an 
Ebola vaccine candidate’s immunogenicity. 
 
Vaccine Safety Profile 
 The other primary indicator of a vaccine candidate’s suitability is its safety 
profile. A vaccine’s usability is limited, possibly to a significant degree, if it causes 
additional health complications, regardless of whether or not it successfully confers 
protection against a given disease. As a result, any vaccine must be thoroughly tested and 
analyzed to make sure that it is safe for humans to use. Unlike immunogenicity, which is 
evaluated through specific techniques, a vaccine’s safety profile is established through 
the frequency and severity of adverse effects within a sample size. Laboratory 
abnormalities, which primarily manifest as decreases in numbers of cells related to the 
immune system, are a secondary contributing factor. While an ideal vaccine displays no 
severe adverse effects and a low frequency of symptoms, it should be noted that there is a 
great deal of risk from contracting or being vulnerable to Ebola due to the deadly nature 
of the disease. By comparison, adverse effects resulting from a vaccine are much less 
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serious and consequently will not weaken an Ebola vaccine candidate’s safety profile 
unless the adverse effects are significant. 
 
Miscellaneous Characteristics that Influence Efficacy 
The vast majority of studies covered in this thesis address the efficacy of the three 
vaccine candidates through the described parameters. However, other factors can 
contribute positively or negatively to the overall efficacy of a vaccine. Certain vaccines 
may function more effectively as part of a combination rather than with a single dose, 
leading to either a stronger or longer-lasting immune response, if not both. Even factors 
that are not directly tied to a vaccine’s characteristics are relevant to an analysis of a 
vaccine candidate. How far a vaccine candidate has progressed in development or even 
how much attention it has received can contribute to a vaccine’s efficacy; a vaccine that 
has progressed to Phase 3 clinical trials and successfully conferred protection against 
Ebola directly is much more compelling evidence than a Phase 1 trial that can only 
measure an antibody response. 
This thesis will analyze the effectiveness of these vaccines through their safety 
and immunogenicity profiles, as well as any defining characteristics that significantly 
influence a vaccine’s efficacy. Through an analysis and comparison of the advantages 
and disadvantages of each vaccine, the rVSV vaccine will stand out as the optimal 
vaccine candidate because its ability to consistently demonstrate a strong immune 
response outweighs its tendency to cause adverse effects more frequently than the other 
vaccine candidates. 
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SPECIFIC AIMS/OBJECTIVES 
The main objective of this thesis is to analyze previous studies on three different 
candidates for Ebola virus candidates, specifically the Zaire species that was responsible 
for the Ebola outbreak of 2014-2016. This thesis will present information on the safety 
and immunogenicity profiles of the three vaccines and compare them to each other, and it 
will select one vaccine as the most effective based on this analysis. By reading this thesis, 
one will be able to learn about the three different Ebola vaccine candidates, how they 
perform, and their strengths and weaknesses. 
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PUBLISHED STUDIES 
Pathogenesis and Pathology 
 The Ebola virus disease is one of the most dangerous and potentially fatal 
diseases that has appeared in the modern era. The specific virus that causes the disease is 
EBOV, an enveloped, negative-stranded RNA virus that is in one of five species in the 
Ebolavirus genera, which itself is a member of the Filoviridae family (de La Vega, 
Wong, Kobinger, and Qiu, 2015). The Ebola virus causes disease by infecting antigen 
presenting cells that are a key part of the innate immune system, including macrophages, 
monocytes, and dendritic cells (Rivera and Messaoudi, 2016). While infection of 
macrophages and monocytes will cause them to release inflammatory mediators such as 
TNF-alpha that will further recruit and expose other macrophages and monocytes to 
infection, the infection of dendritic cells will inhibit their ability to function properly 
(Rivera and Messaoudi, 2016). Dendritic cells play a crucial role in stimulating the T and 
B cells of the adaptive immune system; by impairing the dendritic cells’ ability to 
function, the Ebola virus also weakens the adaptive immune system’s ability to clear out 
the infection (Rivera and Messaoudi, 2016). The adaptive immune system’s weakness is 
highlighted through severe lymphopenia, with a deficient T cell response demonstrated 
through a lack of T cell derived cytokines (Rivera and Messaoudi, 2016). The lack of 
activated T cells also negatively affects B cells as well, as there are reduced numbers of 
IgM and IgG antibodies that could target Ebola because CD4+ T cells play a key role in 
antibody-class switching (Rivera and Messaoudi, 2016). The lack of active dendritic 
cells, T cells, and B cells dramatically decreases the ability of the immune system to 
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respond to an Ebola infection, and the weakened immune system that results is a key 
factor to the pathogenesis of Ebola. 
 The autopsies of deceased Ebola patients have revealed multiple indicators of 
Ebola pathology. Lesions in the form of petechiae and ecchymoses have appeared in 
mucous membranes and parenchymal organs, as well as other signs such as GI tract 
hemorrhaging, abdominal organ congestions, and the enlargement of the liver and spleen 
(Baseler, Chertow, Johnson, Feldmann, and Morens, 2017). The liver in particular 
displays many abnormalities representative of Ebola; hepatocellular necrosis is one of the 
most common histologic indicators of Ebola, and is often combined with other liver 
abnormalities such as congestion, inflammation, lipidosis or cholestasis (Baseler et al., 
2017). On a microscopic level, eosinophilic intracellular viral inclusions have been 
commonly found in hepatocytes, and viral antigens have been frequently detected in liver 
cells such as hepatocytes and Kupffer cells (Baseler et al., 2017). The liver displays signs 
of Ebola infection both on a larger and smaller scale, and is consequently a useful organ 
as an indicator for Ebola pathology. 
Other parts of the body apart from the liver display signs of Ebola pathology as 
well. The spleen and lymph nodes also display lesions, which are represented by 
lymphocyte apoptosis and cellular debris that result from the destruction of those 
lymphocytes (Baseler et al., 2017). Lesions have been seen in many important organs in 
the body, with potentially dangerous symptoms occurring in the lung and kidney (Baseler 
et al., 2017). The lung can display multiple signs such as alveolar edema, hemorrhage, 
and congestion, and similar signs, as well as renal tubular epithelial necrosis, have 
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appeared in the kidneys (Baseler et al., 2017). The pathology in the lung and kidney alone 
can negatively affect the health of an Ebola victim, and the ability of Ebola to spread 
throughout the body gives it the ability to inflict damage upon many different tissues and 
body systems that the body needs to function properly. 
Specific aspects of Ebola have been examined to understand how the Ebola virus 
infects other cells. In particular, one protein that is encoded by the GP gene of the 
Ebolavirus, sGP, is believed to play a key role during Ebola infection (de La Vega et al., 
2015). When Ebola enters the target cell and releases its viral genome, the genome is 
transcriptionally edited to produce pre-sGP, a precursor that is cleaved by proteases such 
as furin to yield sGP (de La Vega et al., 2015). sGP could potentially have multiple 
functions that facilitate Ebola pathogenesis; these include acting as a decoy antigen to 
draw antibodies away from the surface glycoprotein GP1,2 found on the surface of Ebola 
viruses, antigenic subversion of the humoral response, partially restoring the barrier 
function of vasculature, neutrophil inactivation, and bystander apoptosis of B and T cells 
(de La Vega et al., 2015). However, some of these proposed functions, such as bystander 
apoptosis of adaptive immune cells and immune subversion, require conclusive evidence 
or further analysis in order for future researchers to understand the mechanisms by which 
sGP can induce Ebola pathogenesis (de La Vega et al., 2015). Another aspect of sGP that 
needs to be further analyzed is the relationship between the number of sGP produced and 
the level of pathogenicity of a given Ebola virus strain (de La Vega et al. 2015). Despite 
the lack of information regarding the characteristics of sGP and its role in certain aspects 
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of Ebola pathogenesis, it maye nevertheless prove to be an important focus for Ebola 
vaccines and treatments once more information about it is revealed. 
 
Transmission 
One of the reasons why the Ebola virus is so dangerous is because it can be 
transmitted through a relatively simple mechanism. Multiple animals such as 
chimpanzees, monkeys, and in particular the Pteropodidae family of fruit bats can 
potentially carry the virus, and it can be transmitted from animals to humans through 
contact with organs and body fluids such as blood and secretions (WHO, 2017). The 
mechanisms by which humans can contract the virus from each other are similar to those 
by which they can be infected from animals; both health care workers and burial 
practitioners who directly come into contact with other humans are particularly 
vulnerable to infection (WHO, 2017). The relative ease of Ebola transmission is a 
significant contributor to the danger that it poses, and is one of the reasons why contact 
with the infected requires tightly enforced regulation to prevent the spread of the disease. 
 
Clinical Presentation 
The Ebola virus disease has a complex clinical presentation that features many 
different symptoms and contributes to the severity of the disease. While it has an 
incubation period of 2 to 21 days, Ebola fever can happen very quickly and present itself 
in only 5 to 12 days (Casillas, Nyamathi, Sosa, Wilder, and Sands, 2003). Unfortunately, 
many of the early symptoms are common across other diseases such as influenza and 
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malaria, which makes it difficult to conclusively determine the presence of Ebola without 
labwork confirmation (Casillas et al., 2003). The early symptoms of Ebola are 
nonspecific and incredibly varied, and include acute fever, fatigue, vomiting, diarrhea, 
loss of appetite, headache, abdominal pain, and myalgias (West and Von Saint André-Von 
Arnim, 2014). One of the most prominent symptoms found in Ebola victims in Guinea is 
a significant amount of volume loss due to a combination of diarrhea and vomiting, 
which requires aggressive oral and intravenous replacement of the lost fluids to prevent 
more serious health problems, most notably hypo-perfusion associated organ dysfunction 
(Bah et al., 2014). Elevated temperature and pulse-temperature dissociation are more 
compelling and more unique signs of Ebola virus that have been detected in previous 
outbreaks (West and Von Saint André-Von Arnim, 2014). As the disease progresses, it 
begins to develop extensive hemorrhaging of the GI tract, lungs, and gingiva, as well as 
disseminated intravascular coagulation within the vascular bed (Casillas et al., 2003). If 
the central system is affected by the virus as well, then a victim of Ebola may undergo 
convulsions, delirium, or somnolence (Casillas et al., 2003). If the patient is not treated 
and does not recover early on from Ebola, the disease will progress to its final stages, 
leading to multiorgan failure, hypovolemic shock, and ultimately death (Casillas et al.). 
 
Diagnosis 
Although it may be difficult to determine the presence of Ebola because of its 
early similarities with other diseases, there are various techniques that can be used to 
diagnose Ebola. These techniques include ELISA tests, antigen-capture detection tests, 
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serum neutralization tests, RT-PCR assays, electron microscopy, and virus isolation by 
cell culture (WHO, 2017). The WHO in particular recommends automated or semi-
automated NAT tests for routine purposes and rapid antigen detection tests if the NAT 
tests are not easily accessible (WHO, 2017). The WHO also prefers to use whole blood 
from living patients and oral fluid specimens for the deceased, but these specimens are 
incredibly dangerous to use and need to be tightly contained with maximum security both 
for laboratory testing and for packaging purposes (WHO, 2017). Diagnosis of Ebola 
revolves largely around lab work and technology, which will provide accurate 
information about the presence of the disease but must also be handled carefully since the 
preferred specimens are also the main means of Ebola transmission between humans. 
 
The Most Recent Ebola Outbreak 
Some of the earliest recorded outbreaks of Ebola occurred in 1976 in two 
locations, in South Sudan and in the Democratic Republic of Congo (WHO, 2017). 
However, the most complex, large-scale, and well-known outbreak of Ebola occurred in 
2014-2016 (WHO, 2017). The outbreak has caused more than 28,639 cases of Ebola and 
over 11,316 deaths as of February 2016, a far greater number and cost in human lives 
than any recorded cases of Ebola before the outbreak (CDC, 2016). The 2014-2016 Ebola 
outbreak was focused around Sierra Leone, Guinea, and Liberia, with a greater 
concentration of Ebola cases focused within Sierra Leone (CDC, 2016).  
While the devastating effects of Ebola can be most clearly highlighted through the 
number of cases and deaths, the Ebola epidemic also had serious consequences on a 
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social level. The 2014-2016 outbreak significantly crippled the economy of the three 
countries affected, costing an estimated total of 2.2 billion dollars as a result of 
significant decline in both the private sector and in agricultural production, as well as 
restrictions on trade because of the outbreak (CDC, 2016). The outbreak also placed the 
health care workers in Sierra Leone, Liberia, and Guinea at high risk of contracting the 
disease, leading to at least 881 health worker infections and 513 deaths since November 
2015 (CDC, 2016). Liberia and Sierra Leone were more severely affected in terms of 
health care workers, losing 8% and 7% of their health care practitioners to Ebola in 
comparison to Guinea’s 1% (CDC, 2016). The Ebola outbreak also crippled health care 
indirectly, as the health care system was forced to allocate resources to the epidemic and 
away from other diseases such as tuberculosis, malaria, and HIV (CDC, 2016). As a 
result, around 10,600 lives were lost to these diseases, lives that could have potentially 
been saved without the Ebola epidemic interfering with health care efforts in these 
countries (CDC, 2016). Children in particular suffered under Ebola, as nearly 20% of 
cases in the affected countries were children under 15 and more than 17,300 children 
have been orphaned because of the outbreak (CDC, 2016). The children also lacked 
access to education during the outbreak, as the schools were forced to close from June 
2014 to 2015 and around 1848 hours of education were lost as a result (CDC, 2016). 
Ebola proved to be a devastating disease not just to an individual person’s health but also 
to multiple social aspects of entire countries, and the consequences to the economy, 
health care system, and children’s lives may reach far beyond the end of the Ebola 
outbreak itself. 
12 
 
RESULTS 
 There have been many studies conducted on the three vaccine candidates chAd3, 
rVSV, and rAd5. The first studies that will be described for each vaccine will be those 
that measure the efficacy of the vaccine or highlight a vaccine’s immunogenic 
characteristics in animal models, with cynomolgus macaques being one of the most 
commonly used animals for Ebola vaccine studies. The studies after these will be focused 
on human adult trials, starting with trials that analyze the safety profile and immunogenic 
capabilities of a given vaccine candidate without any additional modifications. Any 
additional trials will revolve around vaccine modifications or more advanced stages in 
trial progression, such as a vaccine that is part of a prime-boost regimen or a trial that 
tests the effectiveness of a vaccine against Ebola directly. The studies will be organized 
in this manner to highlight the progression from animal models to human trials and 
establish the overall efficacy of a given vaccine candidate with these different stages. 
 
The ChAd3 Vaccine 
 The chAd3 vaccine is one potential Ebola vaccine that has shown promising 
results based on studies conducted on both NHPs and human adults. In a study that used a 
mouse model to measure the ability of different human-derived, chimpanzee, and simian 
adenovirus vectors to elicit a CD8+ T-cell response, the chAd3 vector was shown to be 
one of the most potent inducers of CD8+ T-cell responses compared to other adenovirus 
vectors that were tested, such as rAd5, sAd16, and chAd63 (Quinn et al., 2013). These 
CD8+ T-cells displayed the ability to co-express IFN-gamma, TNF-alpha, and IL-2 
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(Quinn et al., 2013). This ability of these T-cells to express one or more of these 
cytokines would be used to analyze the ability of a vaccine to induce a T-cell response in 
Ebola trials. The chAd3 vector was also shown to consistently reduce bacterial loads in 
mouse spleens at multiple doses ranging from 1 x 107 PU to 1 x 109 PU, while other 
vectors such as rAd5 and chAd63 could not reduce bacterial loads as effectively at lower 
doses (Quinn et al., 2013). Although these experiments only utilized mice models and did 
not focus on Ebola specifically, the overall protective and immunogenic efficacy of 
chAd3 as a stand-alone vector are important characteristics that would become a focus of 
studies testing its effectiveness as an Ebola vaccine. 
 Studies using animal models more similar to humans would provide more 
concrete evidence of the vaccine’s efficacy against Ebola. In a study conducted on 
cynomolgus macaques, 4 groups of macaques were injected with a single dose of 1 x 1011 
or 1 x 1010 PU of chAd3 encoding EBOV GP and, 5 weeks later, challenged with a lethal 
dose, or 1000 PFU, of EBOV virus (Stanley et al., 2014). All of the macaques in the 
vaccinated group survived the infection without any detectable presence of virus in the 
blood, while the unvaccinated macaques easily succumbed to Ebola by 6 days after the 
infection and presented with viral loads greater than 1 x 107 PFU equivalents per mL in 
plasma (Stanley et al., 2014). However, in a group of 4 macaques with only 1 x 109 PU of 
vaccine, 2 macaques survived without viremia while 2 were killed with viremia similar to 
that of unvaccinated controls (Stanley et al., 2014). This difference in results suggests 
that the vaccine, at least in macaques, begins to lose effectiveness at the lower dose level.  
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Despite the overall difference in health outcomes, when the number of EBOV 
GP-specific antibodies in the macaques were measured through ELISA, both the 1 x 1010 
PU and 1 x 109 PU doses displayed similar titers of GP-specific antibodies (Stanley et al., 
2014). However, the 1 x 1010 PU dose also displayed a higher frequency of peripheral 
blood T-cells secreting cytokines such as TNF-alpha, IFN-gamma, or IL-2 (Stanley et al., 
2014). Since the CD8+ T-cell response is a more reliable indicator of a vaccine’s 
immunogenic ability, the increased presence of cytokine-releasing CD8+ T-cells in the 1 
x 1010 PU dose adds additional support to the finding that the chAd3 vaccine can initiate 
an immune response against Ebola, at least at higher doses.  
The chAd3 vaccine was also tested for its ability to provide durable immunologic 
protection against Ebola with a single shot, and the macaques were given a lethal dose of 
Ebola ten months after a vaccination with 1 x 1010 PU or 1 x 1011 PU dose respectively 
(Stanley et al., 2014). Despite the interval between the vaccination and the infection, the 
1 x 1011 PU was able to protect half of the vaccinated macaques, while unfortunately the 
1 x 1010 PU dose was unable to provide any meaningful protection to the macaques 
(Stanley et al., 2014). Macaques injected with both doses experienced decreases in 
antibody and T-cell responses over a period of 40 weeks; however, the macaques injected 
with a 1 x 1011 PU chAd3 dose displayed higher numbers of both antigen-specific 
antibody titers and memory CD8+ T-cell frequencies at any given point in time when 
compared to the macaques with the 1 x 1010 PU dose (Stanley et al., 2014). Although a 
higher dose may provide durable protection against Ebola to some degree, the data 
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gathered from the macaques suggests that chAd3 is limited in its capacity for long-term 
protection against Ebola. 
The study also explored the possibility of a chAd3 vaccine boosted with MVA to 
see if a prime-boost vaccination could protect against Ebola more effectively than chAd3 
by itself. In the macaques, the combination was administered as a 1 x 1010 PU dose of 
chAd3 vaccine boosted with 1 x 108 PFU of MVA (Stanley et al., 2014). The 
chAd3/MVA vaccine was the only vaccine regimen that could provide 100% protection 
in a group of 4 macaques, as opposed to a second chAd3 boost or a chAd3/chAd63 
heterologous regimen that had survival rates of 20-40% (Stanley et al., 2014). When the 
immunogenicity of chAd3/MVA was compared to other vaccines, the chAd3/MVA 
vaccine recipients possessed the highest number of cytokine-producing CD8+ T-cells, as 
well as the highest number of GP-specific antibodies and the most robust CD4+ T-cell 
response (Stanley et al. 2014). These results suggest that the chAd3/MVA prime-boost 
vaccine can be much more effective as an Ebola vaccine than chAd3 alone, although 
studies focusing on humans and with larger sample sizes would be needed to more 
thoroughly and accurately evaluate the overall efficacy of chAd3. Nevertheless, these 
results show some early promise in chAd3 as an Ebola vaccine candidate. 
The most concrete evidence supporting the efficacy of the chAd3 vaccine comes 
from studies testing the safety and immunogenicity of the disease in human adults. These 
studies were prioritized in the wake of the 2014-2016 Ebola outbreak. One study 
analyzed the efficacy of the chAd3 vaccine against Zaire Ebola in Malian and U.S. adults 
simultaneously. The adults received different doses of vaccine ranging from 1 x 1010 PU 
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to 1 x 1011 PU, although there were more varied doses tested for the Malian group (Tapia 
et al., 2016). Across all doses, the vast majority of adverse effects recorded were mild, 
with no serious effects reported (Tapia et al., 2016). The most common adverse effect 
reported was a fever that occurred in 7 out of 91 Malian participants and 4 out of 20 U.S. 
participants, an effect which was more common in the higher doses and did not last 
longer than 24 hours (Tapia et al., 2016). One Malian and 2 U.S. vaccine recipients had 
fevers greater than 8.5 degrees Celsius, as well as systemic fevers such as fatigue, 
headache, and nausea, though this occurred in a very low percentage of vaccine recipients 
overall (Tapia et al., 2016). In terms of laboratory abnormalities, there were scattered 
cases of lymphopenia and single cases of moderate and severe asymptomatic 
thrombocytopenia, all of which occurred on day 1 of vaccination and resolved by day 7 
(Tapia et al., 2016). The results of the study support the idea that the chAd3 vaccine can 
be safely used, with most of the side effects being minor complications that can easily be 
overcome or remedied. 
 While the safety profile of the vaccine was established through analyzing adverse 
effects and laboratory abnormalities, the immunogenicity of the vaccine was measured 
through the quantities of anti-EBOV GP antibodies and T-cell responses. The average 
antibody titers (GMT) for the vaccine recipients was significantly higher in high-dose 
recipients (1 x 1011 PU) compared to the low-dose recipients (1 x 1010 PU - 5 x 1010 PU), 
with a greater proportion of Malian vaccine recipients with day 28 reciprocal titers of 500 
or higher, 1000 or higher, or 2000 or higher (Tapia et al., 2016). The GMTs for the 
vaccine recipients were highest at 28 days and fell slowly over the course of 12 weeks, 
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although the antibodies had a greater durability when induced by the high dose compared 
to the lower doses (Tapia et a., 2016). In terms of T-cell response, however, the vaccine 
by itself only yielded a small T-cell response overall, with 31% (15 out of 49) of 
participants showing positive CD4+ or CD8+ T-cell responses (Tapia et al., 2016). 
However, the ability of chAd3 to induce T-cell responses increased greatly when the 
vaccine was boosted with MVA, leading to a much higher 85% of vaccine recipients 
experiencing positive CD4+ or CD8+ T-cell responses after the boost (Tapia et al., 2016). 
The chAd3 vaccine was able to induce high numbers of anti-GP antibodies consistently, 
albeit to a greater and more long-lasting effect at higher doses. However, considering the 
difference in percentage of vaccine recipients with a T-cell response with and without 
boosting, the MVA boost may greatly facilitate the vaccine’s ability to directly induce an 
adaptive immune response. 
 Other human studies have yielded promising results for the chAd3 vaccine. A 
phase 1/2a trial conducted at the Centre Hospitalier Universitaire Vandois in Switzlerand 
divided 120 people into groups of 51 with a 2.5 x 1010 PU dose, 49 with a 5 x 1010 PU 
dose, and 20 with a placebo (De Santis et al., 2016). This study did not note any serious 
adverse effects, and most were mild and self-limiting effects that started within the first 
24 hours after injection and ended in less than 48 hours (De Santis et al., 2016). In this 
particular study, the most common local effect was grade 1 pain, while the most common 
systemic effects were fatigue, malaise, and headache (De Santis et al., 2016). Fever was 
also detected in 28% of the vaccine recipients in comparison to 5% of the placebo 
recipients, with higher temperatures being associated with the higher dose group (De 
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Santis et al., 2016). There were also more unique adverse effects that were recorded: one 
such event was “an episode of macroscopic haematuria associated with pain and burning 
with urination and mild left costovertebral angle tenderness at percussion that arose 
within 24 h after injection with low-dose vaccine” (De Santis et al., 2016). A different 
adverse effect was also found in the high-dose group, one event of herpetiform dermatitis 
that arose at day 15 after injection and lasted for two weeks (De Santis et al., 2016). 
While these are among the more serious adverse effects recorded with the chAd3 vaccine, 
the study did not establish a direct connection between them and the vaccine itself. The 
study also analyzed the trial participants for any laboratory abnormalities, such as 
lymphopenias, but all of them were clinically insignificant and transient (De Santis et al., 
2016). Unlike the previous studies, the phase 1/2a trial checked the trial participants for 
adverse effects for up to 180 days after the vaccination had occurred, and only four 
adverse effects possibly related to the vaccine were recorded: an axillary lymph-node 
enlargement in a high dose participant, two cases of fatigue, and one case of mild 
arthralgia in finger joints (De Santis et al., 2016). The phase 1/2a trial did record a wider 
range of adverse effects, some of which were not noticed in previous human trials or 
expected to occur. However, these unique side effects were very isolated and rare cases, 
so they do not significantly detract from the overall safety profile of the chAd3 vaccine. 
 The phase 1/2a trial also yielded high immunogenicity results in addition to a 
strong safety profile. Antibody responses, measured by titers for anti-Ebola glycoprotein 
antibodies, were measured from Day 14 to a peak at Day 28, which is similar to the 
results found in other studies (De Santis et al., 2016). The vaccine, which was able to 
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induce an antibody response in 96% of both the high and low dose groups compared to 
5% in the placebo group, yielded GMT concentrations of 51 μg/mL and 44.9 μg/mL 
respectively, between six to eight times the concentration in the placebo group (De Santis et 
al., 2016). However, the number of antibodies decreased significantly from Day 28 to 6 
months after injection, although the GMTs were still higher than both the placebo group 
and before the vaccine was administered (De Santis et al., 2016). With a placebo for 
comparison, these results support the antibody-inducing effects of the chAd3 vaccine 
against Ebola GP, especially for short-term protection within 1 month. 
 The phase 1/2a trial also examined the ability of the chAd3 vaccine to directly 
induce an immune system response, both for innate and adaptive immunity. The study 
uses IFN-gamma ELISPOT to measure the mononuclear cell response; similar to the 
antibody response, both the high dose and low dose groups demonstrated a mononuclear 
cell response as early as Day 7 which peaked at Day 14 (a median response of around 
180 SFU / million PBMCs), although this response also declined by 180 days (De Santis 
et al., 2016). In addition to the mononuclear response, the chAd3 vaccine induced a 
significant glycoprotein-specific CD4+ and CD8+ T-cell response for both high and low 
doses, with a slightly higher percentage of participants in both groups displaying a CD8+ 
T-cell response (67% and 69% respectively) than a CD4+ T-cell response (57% and 
61%) (De Santis et al., 2016). The additional analysis of the mononuclear cell response 
opens up the possibility of another avenue by which the chAd3 vaccine can provide 
protection against the Ebola virus, and the measurement of the T-cell response offers 
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more substantial support in favor of the chAd3 vaccine’s ability to induce a response in 
the adaptive immune system by itself. 
 Although chAd3 can function as a stand-alone vaccine, it is possible if not likely 
that the vaccine may be more effective as part of a combination. In a very recent study, a 
recombinant version of the chAd3 vaccine was tested: a 1 x 1011 PU dose each of chAd3 
vaccine against both the Zaire virus and the Sudan virus, the most virulent species of 
Ebola virus (Ledgerwood et al., 2017). For 20 participants, 10 of which each received a 
single vaccine dose of 2.0 x 1010 PU or 2.0 x 1011 PU, there were only mild to moderate 
side reactions to the vaccine and only 2 cases of fever in the high dose group, both of 
which occurred quickly after vaccination and resolved within 1 day (Ledgerwood et al., 
2017). Two weeks after vaccination, however, there were reported cases of asymptomatic 
prolonged aPTT in 1 recipient of the lower dose and 2 recipients of the higher dose, 
although these were believed to be caused by induction of antiphospholipid antibody in a 
laboratory assay and not by coagulation or a health complication (Ledgerwood et al., 
2017). Other laboratory anomalies found in previous studies were noticed, such as 
asymptomatic neutropenia or leukopenia, but these were minor grade 1 or grade 2 
abnormalities found in only a few vaccine recipients (Ledgerwood et al., 2017). The 
overall safety profile of the recombinant chAd3 Zaire and Sudan vaccine is not 
substantially different from the chAd3 vaccine by itself, which suggests that it can be 
used safely to protect against both Ebola virus species. 
 The immunogenic capability of the recombinant chAd3 vaccine has been 
supported by both antibody and T-cell responses, similarly to other vaccines. Four weeks 
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after vaccination, anti-Ebola GP antibodies to both the Zaire and the Sudan species were 
detected in a very high percentage of the participants, although the antibody response to 
the Zaire strain (90% and 100% in the low and high dose groups respectively) were 
marginally higher than the response to the Sudan strain (70% and 80%) (Ledgerwood et 
al., 2017). The response at week 4 was stronger than the responses for either week 2 or 
week 8, which follows the finding in other studies that the antibody response is at its 
strongest at week 4 (Ledgerwood et al., 2017). However, 48 weeks after the vaccine was 
administered, the anti-GP antibody titers remained much higher than at pre-vaccination 
and stayed at approximately the same level as the titers in the early weeks of the virus 
(Ledgerwood et al., 2017). The presence of a persistent and durable antibody response is 
a significant difference from the reduced response found with chAd3 as a stand-alone 
vaccine, and offers the recombinant vaccine a substantial advantage in terms of providing 
long-term protection against Ebola. 
 The Ebola-specific T-cell response to the recombinant vaccine followed a similar 
trend to the antibody response. The vaccine produced a greater GP-specific T-cell 
response in week 4 than in week 2 or in week 8, and the GP-specific CD8+ T-cell 
responses to at least one antigen by 4 weeks were 20% in the low dose group and 70% in 
the high dose group, while the CD4+ T-cell responses to either the Zaire or Sudan antigen 
was 30% in and 100% in these groups respectively (Ledgerwood et al., 2017). The 
dramatic difference in T-cell response between groups suggests that, in this particular 
case, the dose contributes significantly to the ability of the recombinant vaccine to 
produce a meaningful T-cell response. However, the peak effectiveness of the vaccine 
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seems to be the same regardless of either the dosage or the presence of another vaccine 
working with chAd3. 
 While the chAd3 recombinant vaccine offers some advantages such as the ability 
to protect against multiple Ebola strains and possibly more durable protection, one of the 
most promising possibilities for the chAd3 vaccine is chAd3 boosted with modified 
vaccinia ankara. The MVA boosted chAd3 vaccine has been tested in cynomolgus 
macaques, and has increased immunogenicity by ten times and protected against Ebola 
from five weeks to ten months (Ewer et al., 2016). In humans, the chAd3-MVA prime-
boost vaccine had a safety profile similar to that of other chAd3 variants, with adverse 
effects that were mostly self-limiting and mild (Ewer et al., 2016). The most common 
local side effect, which seemed more connected to the MVA boost, was local pain, while 
the systemic effects, which were similar to those found in other chAd3 variants, included 
fever, headache, fatigue, and malaise (Ewer et al., 2016). There were also four cases of 
prolonged aPTT, similar to what was found in the recombinant chAd3 study, but these 
cases were believed to be an in vitro artifact and did not indicate any coagulopathy (Ewer 
et al., 2016). The most notable difference between the prime-boost vaccine and other 
variants was an increased frequency of lab abnormalities such as mild or moderate 
lymphocytopenia, but these cases were transient and did not lead to any reported health 
complications (Ewer et al., 2016). The safety results of the chAd3-MVA prime-boost 
vaccine do not differ significantly from the chAd3 vaccine by itself and have not lead to 
any serious concerns. 
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 The immunogenic response in humans, however, has proved more promising than 
the chAd3 stand-alone vaccine. While the antibody response followed a similar trend of 
peaking at day 14 and decreasing by day 28, the antibody titer values for chAd3-MVA 
were 9 times the titer values for chAd3 after 1 week (GMT, 6625 vs. 752.4) and 12 times 
by 4 weeks (GMT, 9007) (Ewer et al., 2016). The durability of the antibody response was 
also markedly different, as the titer values for chAd3-MVA after 180 days remained 
substantially higher the chAd3 vaccine by itself (GMT, 1750 vs. 758) (Ewer et al., 2016). 
The cell-mediated immunity response for chAd3-MVA demonstrated similar 
improvement, as the T-cell mediated response peaked at 7 days after vaccination and 
yielded a much higher ELISPOT value than the chAd3 vaccine at its peak of 14 days (a 
median of 2068 SPC / million PBMCs) (Ewer et al., 2016). 180 days later, the boosted T-
cell response remained much higher than the unboosted response, (SFCs, 498 vs. 84), 
demonstrating a T-cell response durability that has not been witnessed in other variants of 
the chAd3 vaccine (Ewer et al., 2016). The chAd3 vaccine, when boosted with MVA, has 
experienced a dramatic increase in immunogenicity in many criteria that have been used 
to test the chAd3 vaccine; this improved performance, along with a lack of major 
differences in safety profile, may solidify this variant of the chAd3 vaccine as the most 
effective form to use both for short and long-term protection.  
 Although the chAd3 vaccine has a strong safety and immunogenicity profile, it 
does have at least one potential weakness. A small percentage of the human population 
possesses pre-existing antibodies against chAd3, which may limit the vaccine’s ability to 
induce an immunogenic response (Ledgerwood et al., 2017). The amount of anti-chAd3 
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antibodies negatively correlated with CD8+ T-cell responses and even with anti-GP 
antibody response as well (De Santis et al., 2016), although there is some conflict 
regarding the latter among different studies. This aspect of the chAd3 vaccine was not a 
central focus in the studies, but nevertheless is a cause of concern for a portion of the 
population naturally or for patients who wish to take the vaccine repeatedly. 
 
The rVSV-ZEBOV GP Vaccine 
 The rVSV-ZEBOV GP vaccine is one of the most intensely studied vaccines that 
can potentially prevent Ebola virus disease. VSV is part of the Rhabdoviridae family of 
viruses, a negative-stranded RNA virus with a genetic makeup that can produce 5 
structural proteins (Geisbert and Feldmann, 2011). One of the reasons VSV is a viable 
vaccine candidate is because it is relatively harmless as a virus; it rarely infects humans, 
and when it does infect humans it either causes no symptoms or a mild, influenza-like 
illness (Geisbert and Feldmann, 2011). Out of the possible variations of the VSV vaccine, 
the live viral vaccine has the greatest ability to protect against other viral infections, and 
the virus’ genetic flexibility allows for the development of recombinant variations of the 
virus that prominently express foreign viral proteins (Geisbert and Feldmann, 2011). This 
possibility is the fundamental premise behind the rVSV-ZEBOV GP vaccine. 
 The rVSV-ZEBOV GP vaccine has several mechanisms through which it can 
bring about protection against Ebola. A study on rVSV-ZEBOV GP function has 
revealed that antibodies play a key role in the vaccine’s ability to protect against a lethal 
level of Ebola (Marzi et al., 2013). This experiment reduced the CD4+, CD8+, and 
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CD20+ lymphocyte counts of non-human primates before and during vaccination with 
rVSV (Marzi et al., 2013). Although there was a T-cell proliferative boost in response to 
rVSV antigens in all three groups, there was a robust antibody response to vaccination in 
all three groups except for CD4+ depleted animals and animals vaccinated with a 
negative control, which would be ineffective against the Zaire Ebola virus (Marzi et al., 
2013). The CD4+ depleted and negative control animals exhibited signs of Ebola and 
succumbed to the fatal disease (Marzi et al., 2013). The importance of CD4+ T-cells was 
also ruled out by testing animals who had their CD4+ T-cell count but not their antibody 
response depleted, and these animals did not exhibit any signs of disease (Marzi et al., 
2013). The non-human primates only succumbed to disease if they lacked Ebola GP-
specific antibodies, suggesting that this particular aspect of the immune system plays a 
key role in the vaccine’s ability to protect against Ebola. 
 Other potential mechanisms for rVSV-ZEBOV GP involve different aspects of 
the immune system. The rVSV-ZEBOV vaccine has been reported to induce acute gene 
expression changes in macaques a week after vaccination, especially in genes that play a 
role in the innate immune response or antiviral defense (Menicucci, Sureshchandra, 
Marzi, Feldmann, and Messaoudi, 2017). The study that investigated the functions of the 
vaccine discovered that a higher number of these affected genes were present in CD8-
depleted animals and that CD4-depleted animals experienced a delay in the onset of 
Ebola (Menicucci, Sureshchandra, Marzi, Feldmann, and Messaoudi, 2017). This led to 
the conclusion that the CD8+ T-cell response induced by rVSV vaccine can contribute to 
protection against Ebola, but also that this protection is limited (Menicucci, 
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Sureshchandra, Marzi, Feldmann, and Messaoudi, 2017). CD8+ T-cell immunity may be 
a secondary mechanism by which the rVSV-ZEBOV GP protects against Ebola, but it has 
only recently been revealed and is not as high of a priority as antibody response, a central 
focus of many studies testing the efficacy of the vaccine. 
 There have been several studies revolving around the recombinant VSV vaccine 
that have tested its efficacy against Ebola and other diseases in different animals, even 
before the 2014-2016 Ebola outbreaks increased the priority of finding an Ebola vaccine. 
A different variant of the rVSV-GP vaccine was used against influenza in mice, and 
while the vaccine did not completely counteract the influenza, it successfully protected 
against weight loss and lethality from more severe pathogenesis if multiple immunizing 
doses were administered (Roberts, Buonocore, Price, Forman, and Rose, 1999). The 
rVSV-ZEBOV GP vaccine itself was tested for long-term protection in rodents, and the 
vaccine was able to yield a 100% survival rate in guinea pigs that were exposed to Ebola 
18 months after vaccination, without any viremia or clinical signs 3 months after 
vaccination (Wong et al., 2014). However, the IgG antibody responses declined 12 
months after vaccination in elder mice, which suggests that the vaccine may not be able 
to provide long-term protection in older animals (Wong et al., 2014). Mice and rodents 
are not the most accurate model to determine the efficacy of a vaccine in humans, so 
these trends may not reflect the performance of the vaccine in clinical trials. However, 
the studies on mice presented enough evidence to merit further investigation of rVSV-
ZEBOV GP as a potential vaccine against Ebola. 
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 Other studies have investigated different characteristics of the rVSV-ZEBOV GP 
vaccine in cynomolgus macaques, which can offer more useful information on how the 
vaccine may perform in humans. A 2008 study failed to observe adverse effects from the 
vaccine in over 90 macaques, and when the vaccine was tested in immunocompromised 
SHIV-infected macaques, it did not cause any illness and offered sufficient protection 
unless the macaque’s immune system was severely compromised (Geisbert et al., 2008). 
Different ways of administering the vaccine were also tested; the rVSV-ZEBOV GP 
vaccine could induce humoral and cell-mediated immune responses in cynomolgus 
macaques whether it was given intra-nasally, orally, or through intramuscular injection 
(Qiu et al., 2009). None of the macaques fell victim to the disease, and the antibody 
response for intranasal administration was actually higher than for intramuscular 
injection, which could make it easier to administer in a large-scale vaccine program (Qiu 
et al., 2009).  
However, some of the vaccine’s limitations were also revealed through the 
experiments on macaques. A more recent study tested whether or not the vaccine could 
work as a treatment after Ebola exposure as well as a preventative vaccine; similar to 
previous studies, the results revealed that rVSV-EBOV is highly effective and fast-acting 
when administered at the time of exposure (Marzi et al., 2016). However, the study also 
discovered that the vaccine had only a short time window in which it could treat 
postexposure Ebola, which reduces its efficacy if the vaccine recipient has been infected 
for quite some time (Marzi et al., 2016). This is possibly because a vaccine administered 
too late will be unable to develop a meaningful immune response against Ebola before 
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the virus starts to damage the body. This limits the vaccine to more traditional uses, 
although the studies on macaques all support its protective ability otherwise. The 
promising results from these studies have provided plenty of incentive to test the rVSV 
vaccine’s efficacy in humans especially with the recent Ebola outbreaks, and it has 
become one of the most scrutinized vaccines in human clinical trials. 
 Many organizations, including the WHO, have investigated the safety and 
immunogenicity profile of the rVSV vaccine. In one of the more well-known trials, 
labeled as NCT02287480, the WHO gathered a consortium of clinical research centers to 
include 250 volunteers in a Phase 1/Phase 2 trial in Geneva, Switzerland that aimed to 
“assess the safety and tolerability of the VSV-ZEBOV vaccine when administered to 
health volunteers at a lower or higher vaccine dose…” (ClinicalTrials.gov, 2016). This 
trial was quite similar to others being conducted in Hamburg, Germany, Lambaréné, 
Gabon, and Kilifi, Kenya, and the doses covered in all of them ranged from 300,000 PFU 
to 50 million PFU (Agnandji et al., 2016). All of them displayed a similar and 
surprisingly high level of reactogenicity as a result of the rVSV vaccine to the point that 
the Geneva study was temporarily halted by a safety hold (Agnandji et al., 2016). 
Although there were no serious adverse effects reported, almost 92% of the 158 
participants exhibited either a mild or moderate adverse effect, with 10% of participants 
in Kilifi and Hamburg and 22% of participants in Geneva exhibiting a grade 3 symptom 
(Agnandji et al., 2016). Fever was one of the main symptoms identified as a result of 
vaccination, ranging from 13% of participants in Lambaréné to 25% in both Hamburg 
and Geneva and 30% in Kilifi (Agnandji et al., 2016). While other symptoms were noted, 
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such as pain, headache, chills, and fatigue, and most of these symptoms occurred early 
and subsided quickly (within 24 hours of vaccination and symptom manifestation 
respectively), the most symptom that can jeopardize the viability of the vaccine is 
arthritis (Agnandji et al., 2016). Eleven participants in Geneva suffered from arthralgia, 8 
of which received a 10 million PFU dose and 3 of which received a 50 million PFU dose, 
and nine of those eleven ultimately developed mild arthritis (Agnandji et al., 2016). Three 
of the participants with arthritis developed a further complication in the form of a 
maculopapular rash, which occurred between 7-9 days after vaccination and lasted from 
one to two weeks (Agnandji et al., 2016). 
 Laboratory anomalies were also found frequently in vaccines. In Lambaréné, 60% 
of patients who received a 300,000 PFU dose and 42% of those who received a 3 million 
PFU dose exhibited transient leukocytopenia, while in Geneva, 71% and 53% of 
participants exhibited a decreased number of lymphocytes and neutrophils respectively 
(Agnandji et al., 2016). There were also low levels of rVSV-ZEBOV RNA and viremia 
detected in many participants, ranging from 40% of Lambaréné participants who received 
a 300,000 PFU dose to 95% of Lambaréné participants who received a 3 million PFU 
dose (Agnandji et al., 2016). The low cell counts and viremia were ultimately temporary, 
as both conditions resolved themselves in 1-3 days and 7 days respectively (Agnandji et 
al., 2016). However, while these particular abnormalities may be short-lived, the rVSV-
ZEBOV vaccine has caused a high frequency of adverse effects in multiple parts of the 
world, and the possibility of arthritis as a vaccine-related condition weakens its safety 
profile despite the lack of serious adverse effects. 
30 
 
 Although the rVSV-ZEBOV may be a reactogenic vaccine, it is fortunately an 
immunogenic vaccine as well. Antibody responses are the primary standard by which 
immunogenicity is measured, and ZEBOV-GP specific antibodies were detected in all of 
the vaccine recipients after 28 days, following similar anti-GP GMT and distribution 
patterns in each study (Agnandji et al., 2016). Even the lowest dose, 300,000 PFU in 
Lambaréné, was immunogenic, although the lower doses did result in lower response 
rates (Agnandji et al., 2016). In addition to anti-GP antibodies, neutralizing antibodies 
were studied using PsVNA50. These antibody levels were either low or absent before 
vaccination, but significantly increased (in 107/126 vaccine recipients in Lambaréné) 
after any dose of rVSV-ZEBOV GP was administered (Agnandji et al., 2016). The levels 
of anti-GP and neutralizing antibodies at day 28 were strongly correlated to each other, 
but a higher dose can lead to both a similar anti-GP titer and a higher neutralizing 
antibody titer; in Geneva, a dose of 50 mill PFU yielded a similar anti-GP titer result to 
10 mill PFU (GMT, 1780 vs. 1064), but a much higher PsVNA titer (GMT, 273 vs. 99) 
(Agnandji et al., 2016). These discrepancies would also continue in long-term 
measurements of rVSV-ZEBOV GP’s efficacy. Six months after immunization, GP-
antibodies persisted across all participants without any significant decrease, with a day 
180/day 28 GMR of 1.59 potentially suggesting a possible increase in antibodies 
(Agnandji et al., 2016). However, the neutralizing antibodies experienced a decline over 
an extended period of time, persisting in only 23%, or 28/120 participants (Agnandji et 
al., 2016). These 4 studies, taken in different parts of the world and with many different 
doses, consistently demonstrate both the immunogenic and reactogenic characteristics of 
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the rVSV-ZEBOV GP vaccine. The 180-day presence of antibodies in particular offers 
the vaccine some potential as a long-term protection against Ebola that was not present in 
vaccines such as chAd3. 
 The high prevalence of adverse effects, particularly arthritis in Geneva, has raised 
the question of whether or not a lower dose can lead to a lower frequency of adverse 
effects. After the study hold, 51 participants received a lower dose of rVSV (3 x 105 
PFU) as opposed to 59 participants each who received a higher dose before (1 x 107 PFU 
or 5 x 107 PFU) (Huttner et al., 2015). Both doses yielded no serious adverse effects, but 
there was only a slight decrease in frequency of adverse effects, 88% in low-dose vaccine 
recipients vs. 98% in high-dose vaccine recipients and 15% in placebo (Huttner et al., 
2015). However, the frequency of individual symptoms decreased greatly in the low-dose 
group compared to the high-dose group: these include local pain (22% of low-dose 
participants vs. 76% in high-dose participants), subjective fever (27% vs. 65%), objective 
fever of 38 degrees Celsius or greater (2% vs. 25%), and myalgia (39% vs 67%) (Huttner 
et al., 2015). The adverse effects of the vaccine also manifested later in low-dose vaccine 
recipients, as 19% of 133 low-dose vaccine recipients vs. 5% of 248 high-dose vaccine 
recipients experienced effects after day 2, and the low-dose vaccine recipients also 
recovered more quickly with a median of 1 day after symptom manifestation (Huttner et 
al. 2015). 
Vaccine recipients who received a lower dose of rVSV experienced less severe 
laboratory abnormalities as well as less frequent symptoms. Decreases in lymphocyte, 
neutrophil, and platelet counts occurred in the same number of days for both low-dose 
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and high-dose vaccine recipients, but the decreases were much less severe in the low-
dose vaccine recipients (Huttner et al., 2015). Viremia detection by RT-PCR similarly 
favored the lower dose; only 20% (10/51) of low-dose vaccine recipients had detectable 
viremia compared to 90% of high-dose vaccine recipients (46/51), and the viremia itself 
was less severe compared to the high-dose vaccine recipients (Huttner et al., 2015). Both 
the laboratory irregularities and individual adverse effects are much less prominent in the 
lower dose of the rVSV-ZEBOV GP vaccine compared to the higher dose, which 
provides evidence that a lower dose can indeed be safer for vaccine recipients. 
However, the most serious complications related to the vaccine, arthralgia and 
arthritis, are still prevalent even with the lower dose. After a median of 10 days post-
immunization, roughly the same frequency of vaccine recipients, 25% (13/51) for low-
dose vs. 22% (11/51) for high-dose, suffered from arthralgia, and 12 of the 13 were 
confirmed to have arthritis (Huttner et al., 2015). However, unlike the high-dose 
participants, the median age was significantly higher in those with arthritis compared to 
those without it (51.8 vs. 36.7), suggesting that age can play a significant role in arthritis 
development as long as the dose is not too high (Huttner et al., 2015). These findings 
suggest that, while age may contribute to arthritis vulnerability and that younger patients 
are more suited to the vaccine, arthritis is unfortunately an inherent problem with the 
rVSV-ZEBOV-GP vaccine itself. 
Another concern regarding low doses of the vaccine is that the antibody response 
may not be as strong. Although the vaccine was able to definitively induce an anti-GP 
antibody response regardless of the dose, the GMT for the low dose was lower in 
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comparison to the GMT for the higher dose (GMT, 344.5 vs. 1064.2) (Huttner et al., 
2015). The neutralizing antibody response was also much less likely to occur in low-dose 
vaccine recipients, as only 59% (30/51) of low-dose vaccine recipients exhibited 
neutralizing antibodies in comparison to 92% (44/48) of high-dose vaccine recipients 
(Huttner et al., 2015). By reducing the dose of the rVSV vaccine, both its reactogenic and 
its immunogenic capabilities were weakened, and the presence of neutralizing antibodies 
is much less certain. However, an antibody response is still induced even at a lower dose, 
which may be enough to functionally protect against Ebola. 
Other phase 1 studies have tested the safety and efficacy of the rVSV vaccine in 
America. Two studies were conducted in different locations in Maryland, offering similar 
results to those found in the African and Western European studies. These studies tested 
dose levels at 3 million PFU, 20 million PFU, and 100 million PFU, with 10 people 
receiving these doses at each site (Regules et al., 2017). However, at one of these sites, a 
second identical dose was administered 28 days after the initial dose, creating a new 
variable not seen in previous studies (Regules et al., 2017). There were no severe adverse 
effects reported, but unlike past studies there was no significant correlation between 
frequency of adverse effects and dose (Regules et al., 2017). Similar to the past studies, 
mild or moderate pain was a common local symptom reported in many of the participants 
(Regules et al., 2017). Objective fever was noted in 20 out of 60 vaccine recipients: 18% 
(11) reported grade 1 fever, 12% (7) reported grade 2 fever, and 3% (2) reported grade 3 
fever (Regules et al., 2017). The fevers developed 12-24 hours after vaccination, 
similarly to other systemic symptoms such as headache, myalgia, and fatigue, and the 
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vast majority of individuals recovered by 1 day after vaccination (Regules et al., 2017). 
However, there were unique, isolated adverse events that ultimately resolved without 
further complications, such as unilateral conjunctivitis in 1 volunteer, oral ulcers in 5 
volunteers, 3 patients with cervical lymphadenopathy, and infectious colitis in 1 
volunteer (Regules et al., 2017). Interestingly, although 19 patients exhibited arthralgia, 
there were no reported cases of arthritis, a significant difference from the studies in 
Europe or Africa where arthralgia was frequently followed by arthritis (Regules et al., 
2017). For patients who received a second dose, the reactogenicity was less severe than 
the first dose, which suggests that the vaccine can be used with relative safety with 
repeated doses (Regules et al., 2017). Although the safety profile for the rVSV vaccine is 
similar to that of previous studies in terms of common local and systemic symptoms, the 
lack of arthritis and the presence of more unique complications is a notable deviation. 
The laboratory results in the American studies did not reveal any significant 
complications as a result of the vaccine. The majority of the laboratory anomalies 
occurred after the first dose, and include transient mild-to-moderate lymphopenia (24/60), 
neutropenia (14/60 participants), and asymptomatic grade 2 thrombocytopenia (1 
individual), all of which were resolved by day 7 (Regules et al., 2017). The study 
participants also exhibited rVSV viremia 1-3 days after vaccination, but this frequency 
decreased to 20% of participants after vaccination and all the cases were fully resolved by 
day 14 (Regules et al., 2017). These results are more closely aligned with what was 
established in previous studies, and are ultimately less of a concern. 
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The immunogenicity of the vaccine is also firmly supported in this study. Only a 
single dose was necessary to induce an IgG response, and all patients developed anti-GP 
antibodies by day 28 with a majority in each group (85-90%) developing them by day 14 
(Regules et al., 2017). Groups with doses of 20 million PFU or 100 million PFU did 
exhibit a higher GMT than the 3 million PFU dose both on day 14 (GMT, 857 and 888 
vs. 283) and day 28 (GMT, 4079 and 4079 vs. 1300), with a significant increase in titers 
for all groups from day 14 to day 28 (Regules et al., 2017). However, all of the groups 
that were given a second dose showed another increase in titers from day 28 to day 56 
(GMT, 1300 -> 4222 for 3 million PFU, 5198 -> 7352 for 20 million PFU, 3676 -> 
11143 for 100 million PFU), whereas only the 3 million PFU group had an increase in 
antibody response without a second dose (Regules et al., 2017). However, despite the 
increase in antibody titers from day 28 to day 56, there was no significant increase in 
titers between the single and second dose groups after 180 days, suggesting that long-
term protection is not significantly affected by a second dose (Regules et al., 2017). 
The neutralizing antibody response followed different patterns than the anti-GP 
antibody response. The strength of the neutralizing antibody response depended on the 
strength of the dose, much like the anti-GP antibody titers; the titers for 100 million PFU 
were higher than the titers for 3 million PFU both on day 14 (GMT, 127 vs. 39) and day 
28 (GMT, 461 vs. 223) (Regules et al., 2017). There was no significant difference in 
titers at day 28 between the single and second dose groups, and while the vaccine groups 
exhibited a temporary increase in titers one month after revaccination, this trend was 
ultimately reversed by two months after revaccination (Regules et al., 2017). However, 
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groups without a second dose actually experienced a decrease in neutralizing antibodies 
from day 28 to 56, even though there was again no major difference between doses at day 
180 (Regules et al., 2017). These results suggest that while dose does influence the 
strength of antibody responses both for anti-EBOV GP antibodies and neutralizing 
antibodies, a second dose temporarily bolsters the anti-GP antibody response while also 
temporarily protecting against a reduction in neutralizing antibodies. However, since 
neither parameter was significantly affected by the presence of an extra dose at 180 days, 
a second dose administration may only be useful for short-term protection and may not be 
effective in the long-term. 
  Despite the reactogenicity of the rVSV-ZEBOV-GP vaccine, its immunogenic 
capabilities and the absence of a severe adverse events were considered acceptable 
enough to progress the vaccine into Phase 3 trials. A large scale Phase 3 trial has been 
conducted in Guinea by the World Health Organization and several countries and 
organizations such as Norway and Canada, and interim results of this study suggest that 
the vaccine is effective in protecting against Ebola if it is administered within 10 days 
after vaccination in a person who has not been previously infected (PharmaBiz, 2015). 
Unlike previous studies, the phase 3 trial directly tested the vaccine’s ability to protect 
against the virus itself rather than through antibody responses, and can therefore provide 
the most accurate data about the vaccine’s overall efficacy. 
The phase 3 trial were conducted inside Guinea, one of the countries that had 
suffered the most during the 2014-2016 Ebola outbreak. Unlike other studies, this trial 
was a ring vaccination trial, which is designed to vaccinate “a cluster of individuals at a 
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high risk of infection, owing to their social or geographic connection to a confirmed 
index case” (Henao-Restrepo et al., 2015). A single dose of 2 x 107 PFU rVSV-ZEBOV 
was administered intramuscularly to a total of 7651 participants who were divided into 90 
clusters, 48 of which were given an immediate vaccination and 42 of which had their 
vaccination delayed by 21 days (Henao-Restrepo et al., 2015). Of all of these 
participants, 2014 were given an immediate vaccination and 1498 were given a delayed 
vaccination (Henao-Restrepo et al., 2015). Ten days after the randomization and 
vaccination process, not a single case of Ebola was identified in the immediate 
vaccination group and only 16 cases were detected in the delayed vaccination group; the 
vaccine demonstrated a near 100% efficacy in both groups (Henao-Restrepo et al., 2015). 
Even when the efficacy calculation was expanded to include individuals eligible for 
vaccination (3075 immediate and 2380 delayed), only 6 cases of Ebola in immediate 
detection and 16 cases in delayed vaccination were detected, and the vaccine still 
demonstrated a 75.1% effectiveness at the cluster as opposed to individual level (Henao-
Restrepo et al., 2015). The results of the phase 3 clinical trial are incredibly promising, as 
the vaccine quickly and effectively protected against the Ebola virus disease in a large-
scale population that was directly suffering from the epidemic, which gives it a large 
amount of credibility as a vaccine candidate. 
However, even this phase 3 trial, as promising as it may be, possesses some 
limitations. The safety and adverse effects were not listed in the interim results for the 
study, and the frequency of adverse effects in previous studies suggests that they may be 
quite common in the ring vaccination trial. There was also some statistical uncertainty 
38 
 
regarding the vaccine efficacy itself: the study required a p-value of 0.0027 to be declared 
successful, but the actual p-value was 0.0036, so the vaccine did not meet this specific 
requirement despite otherwise demonstrating vaccine efficacy (Krause, 2015). There was 
also a difference in how many individuals received the vaccine, as the immediate 
vaccination clusters had an average of 42 participants, while the delayed vaccination 
clusters had an average of 57 participants, so the Ebola virus has a naturally increased 
chance of appearing in the delayed vaccination clusters based on the difference in 
individuals (Krause, 2015). However, despite these flaws in the phase 3 trial, the rVSV-
ZEBOV-GP vaccine overall has successfully demonstrated a substantial level of efficacy 
in providing protection against the Ebola virus disease in a large population, which opens 
the possibility for it to be developed more rapidly and for widespread use. 
 One of the primary weaknesses for the vaccine overall is the high frequency of 
adverse effects and the presence of arthritis in a few vaccine recipients. The VSV-
EBOVAC project, which consists of twelve vaccine research institutes from multiple 
continents, has been initiated in order to understand the molecular signatures underlying 
the rVSV vaccine’s reactogenicity (Medaglini, Harandi, Ottenhoff, Siegrist, and VSV-
EBOVAC Consortium, 2015). This project will use state-of-the-art technologies for its 
systems analysis, including previously un-used analyses such as transcriptomic and 
metabolomics profiling (Medaglini et al., 2015). Ebola cases have not been reported after 
later than 6 days after vaccination, which suggests that innate or early adaptive immune 
systems are primarily responsible for the protective effect of the vaccine; therefore, it is 
possible to analyze and profile the immune responses early on while the vaccine is 
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generating a response against Ebola (Medaglini et al., 2015). This project can potentially 
reveal and help others to understand the mechanisms behind the reactogenicity of the 
rVSV-ZEBOV-GP vaccine, and help efforts worldwide to develop a safe and effective 
vaccine against Ebola in the future. 
  
The Ad5 Vaccine 
 The Ad5 vaccine is a third vaccine that displays potential as a vaccine candidate. 
Some of the vaccine’s immunogenic properties have been determined through 
experimentation with cynomolgus macaques. With these macaques, it has been found that 
CD8+ T-cells are required for the rAd5-EBOV vaccine to successfully protect against 
Ebola virus disease (Sullivan et al., 2011). Two macaques that were not vaccinated had 
elevated AST levels reflective of pathogenic Ebola changes and were killed in 8 days, 
while five vaccinated macaques not depleted with CD8+ T-cells had normal AST levels 
and survived (Sullivan et al., 2011). However, four out of five macaques that were 
vaccinated but had their CD8+ T-cells depleted showed elevated AST and viral loads like 
the vaccinated macaques, but the infection took longer to develop and death occurred 
later, in 10-14 days instead (Sullivan et al., 2011). Other factors, such as a transfer of 
polyclonal IgG antibodies and depletion of B cells, did not significantly affect survival 
outcomes (Sullivan et al., 2011). Although only twelve macaques were used in this 
experiment, the study focused on understanding immune mechanisms rather than 
measuring vaccine efficacy, and it provides some insight on the importance of CD8+ T-
cells for the rAd5 vaccine. 
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 The Ad5 vaccine was also shown to have some potential as a postexposure 
treatment in NHPs. Several macaques were exposed to a lethal Ebola challenge, and 67% 
(6/9) of macaques who were treated 30 minutes after infection with the vaccine survived 
the disease (Wong et al., 2015). The three animals who didn’t survive after treatment also 
had a longer mean survival time compared to the ones that did, lasting 11 to 13 days as 
opposed to a survival time of around 7 days in untreated macaques (Wong et al., 2015). 
By contrast, postexposure treatment was less successful 24 hours after infection, as only 
one out of four macaques survived and the macaques that perished had a survival timer 
similar to that of the unvaccinated macaques (Wong et al., 2015). All of the surviving 
macaques had anti-Ebola GP levels increased by 14 days after infection, an antibody 
response that was maintained in the macaques by 28 days (Wong et al., 2015). Similar to 
the previous study, this one used only a few macaques, and the small sample size makes 
it difficult to determine if this is an accurate representation of rAd5’s capabilities. 
However, the results of the study do show that the vaccine induces an antibody response 
that may protect against Ebola not just before exposure, but also after exposure as long as 
treatment occurs very quickly. 
 One of the biggest concerns regarding the rAd5 vaccine’s efficacy that has not 
played a significant role in other vaccines is the presence of anti-Ad5 neutralizing 
antibodies in humans. Unlike other adenoviruses, a large portion of the human population 
has pre-existing Ad5 Nab (Barouch et al., 2011). These percentages reach very high 
levels in places such as South Africa, Kenya, Uganda, and Thailand, where Ad5 
seroprevalence reaches as high as 87.5%-89.5%, 90.5%, 86.4%, and 82.2% respectively 
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(Barouch et al., 2010). The magnitude of Ad5 Nab presence is also significant, with 61.1-
78.7% of adults in these regions possessing a high Ad5 Nab titer (>200) and 25.1-46.8% 
possessing a very high titer (>1000) (Barouch et al., 2010). Even places such as the 
United States can have a prevalence of 37%, which is still a sizable portion of the 
population (Nwanegbo et al., 2004). The common presence of anti-Ad5 neutralizing 
antibodies can significantly limit the effectiveness of the vaccine, and it is a factor that 
has been accounted for in many human studies uniquely for the rAd5 vaccine. 
 While the studies of macaques help to define some of the characteristics of the 
rAd5 vaccine, the majority of information on safety and immunogenicity of the vaccine is 
derived from trials with the vaccine in humans. A study that occurred before the 
devastating Ebola outbreak of 2014-2016 tested the safety and immunogenicity of two 
different doses, 2 x 109 PU (12 participants) and 2 x 1010 PU (11 participants), in 
comparison to 8 placebo recipients for each group (Ledgerwood et al., 2010). Half of the 
participants in each group had a high level of pre-existing Ad5 neutralizing antibodies (> 
500), while the other half had a low or non-existing level (<500) of pre-existing Ad5 
neutralizing antibodies (Ledgerwood et al., 2010). The vaccine did not have any severe 
adverse effects, with the most common local symptom being mild pain in 58.3% (7/12) 
and 72.7% (8/11) of vaccine recipients in the low does and high dose groups respectively 
(Ledgerwood et al., 2010). The most common systemic symptoms were mild headache, 
myalgia, and malaise, with a few scattered moderate cases (Ledgerwood et al., 2010). 
There were only three adverse effects that were given significance by the study: 2 cases 
of aPTT, one for each dose, that normalized 4-8 weeks after the antiphospholipid 
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antibody faded away, and 1 case of grade 3 fever in a high-dose vaccine that appeared 
within 24 hours of vaccination and resolved itself over several hours (Ledgerwood et al., 
2010). Overall, the rAd5 vaccine had a strong safety profile for both the low dose and the 
high dose. 
 The vaccine’s immunogenic response was not ubiquitous, however. For the low 
dose, only 50% of the participants had an anti-GP antibody response 4 weeks after 
vaccination, which reduced to 33% 48 weeks after (Ledgerwood et al., 2010). These 
percentages were only slightly higher for the high dose; 55% of participants had an 
antibody response by week 4, and 40% by week 48 (Ledgerwood et al., 2010). The Ad5 
seronegative subjects had a higher antibody response rate and magnitude than the 
seropositive subjects, which is likely one of the reasons why the overall antibody 
response rate is lower for this particular vaccine (Ledgerwood et al., 2010). The Ebola-
specific T-cell responses were also less prevalent in comparison to other vaccines, as only 
45% of low-dose vaccine recipients and 25% of high-dose vaccine recipients had a GP-
specific T-cell response 4 weeks after vaccination, although the magnitude of responses 
was greater in the higher dose (Ledgerwood et al., 2010). Similarly, only 33% of low-
dose vaccine recipients and 64% of high-dose vaccine recipients expressed a GP specific 
CD4 response, and only 27% of high-dose vaccine recipients and 0 low-dose vaccine 
recipients expressed a CD8 T-cell response 4 weeks post-vaccination (Ledgerwood et al., 
2010). By contrast, all of the patients had a positive Ad5 neutralizing titer after 
vaccination, as well as a slight increase in Ad5 T-cell response (Ledgerwood et al., 2010). 
While the rAd5 vaccine is capable of inducing an immunogenic response, this response 
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was not demonstrated consistently across the study participants and demonstrated some 
dependency both on dose and Ad5 seroprevalence. 
 Since the Ebola outbreak of 2014-2016, there has been an increased focus on 
developing Ebola vaccines for clinical use, including rAd5. One of these studies was a 
phase 1 trial measuring the safety and immunogenicity of the rAd5 vaccine in China.  
The study administered doses of 4.0 x 1010 PU, 1.6 x 1011 PU, and placebo to 40 people 
each via injection (Zhu et al., 2015). Although pre-existing Ad5 immunity was not 
believed to play a major role in safety profile, the overall prevalence of adverse effects 
was somewhat high, with 68% of low-dose participants and 90% of high-dose 
participants reporting a solicited adverse reaction in comparison to 48% of placebo 
recipients (Zhu et al., 2015). While there were no serious adverse effects reported, the 
most common local dose was a mild pain at the injection site in 35% of the low dose 
participants and 73% of the high dose participants, with mild redness appearing more 
frequently in the latter group (Zhu et al., 2015). On the other hand, the most common 
systemic adverse reaction reported was fever, with only a 15% occurrence of grade 1 
fever in both doses and an 18% of grade 2 fever for the high dose participants only (Zhu 
et al., 2015). The presence of laboratory anomalies was similarly low, with only 4 low-
dose participants and 5 high-dose participants experiencing a temporary decrease in 
WBC count (Zhu et al., 2015). While there may have been a high frequency in adverse 
effects, many of these effects in both groups seem to be acceptably mild (eg. local pain), 
and the study otherwise demonstrates a strong safety profile for the rAd5 vaccine. 
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 The phase 1 trial also demonstrated the rAd5 vaccine’s immunogenicity despite 
the factor of pre-existing immunity to the vaccine. Although there were no Ebola GP-
specific antibody responses present 7 days after vaccination, the antibody response 
increased significantly at day 14 and up to day 28 in both the low and high dose groups 
(Zhu et al., 2015). The placebo group did not experience any notable antibody response, 
and the vaccine was more successful in inducing an antibody response in the high dose 
compared to the low dose (GMT, 1305.7 vs. 682.7) (Zhu et al., 2015). However, a 
majority of participants (75-85%) were positive for Ad5 neutralizing antibody and many 
of these (55-63%) had these antibodies at high levels; participants with a high level of 
Ad5-neutralizing antibodies experienced a significantly weaker antibody response (GMT, 
1592.5 vs. 341.4 for low dose, 2231.8 vs. 946.5 for high dose) (Zhu et al., 2015).  
In terms of GP specific T-cell responses measured by ELISPOT, there was no T-
cell response at baseline, but responses for both low and high doses increased to their 
peak at day 14 (465 vs. 765 SFU/million PBMC), before decreasing by day 28 (95 vs. 
210 SFU/million PBMC) (Zhu et al., 2015). In both cases, the high dose induced a 
stronger response than the lower dose. Similar to the antibody response, the presence of 
anti-Ad5 antibodies weakened the T-cell response in the vaccine groups, but even in Ad5 
seropositive individuals, the high dose group still yielded a peak T-cell response higher 
than what the low dose could achieve at 610 SFU/million PBMC (Zhu et al., 2015). The 
presence of CD4 and CD8 T-cell responses was also measured through staining for 
immune cytokines such as IFN-gamma, TNF-alpha, and IL-2 (Zhu et al., 2015). Both the 
CD4 and CD8 T-cell responses increased after vaccination for both doses by day 14, with 
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the magnitude of these responses higher in higher dose individuals and individuals with 
low levels of anti-Ad5 antibody (Zhu et al., 2015). This preliminary report displays a 
stronger safety and immunogenicity profile than the previous study, demonstrating 
detectable antibody and T-cell responses even with the presence of Ad5 neutralizing 
antibodies potentially weakening the vaccine. 
While the preliminary report from the Phase 1 China study covered the overall 
safety and immunogenicity profile of the rAd5 vaccine, a final report from that study 
would include information on immunity duration that was previously unavailable. The 
study participants had their anti-Ebola GP specific antibodies examined at days 112 and 
168, with the antibody titers for the high dose (GMT, 856.6 and 575.5) higher than the 
low dose (GMT, 386.4 vs. 197.9), although both groups had much higher titers values 
than the placebo group, which only had a GMT of 5.0 (Li et al., 2016). The presence of 
pre-existing Ad5 neutralizing antibodies had a significant role in the vaccine’s long-term 
protective capabilities; individuals with a high Nab count had both weakened anti-GP 
antibody responses and an increased decay rate of antibody titers, particularly for the low 
dose (Li et al., 2016). By contrast, individuals with low levels of Nab had only a marginal 
decrease in anti-GP antibody titers (Li et al., 2016). The results from later months suggest 
that rAd5 may be effective for long-term protection against Ebola, as long as the dose is 
higher and the vaccine recipient in question is Ad5 seronegative. 
The T-cell responses, however, followed a different pattern. Although the 
presence of GP specific T-cells had peaked by day 14, they had declined gradually to the 
point that the counts at day 168 were similar between the vaccine and the placebo (Li et 
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al., 2016). Both the low and high dose groups had a weak median of 5 SFU/million 
PBMC and 10 SFU/million PBMC respectively (Li et al, 2016). This pattern would be 
similar but not as severe for cytokine-positive CD4 and CD8 T-cells, which would also 
decrease by 168 days but still remain detectable (Li et al., 2016). These results suggest 
that, if only a single dose is used, that the rAd5 vaccine is limited in its ability to generate 
a long-term T-cell response. 
However, the study also experimented with a homologous boosting vaccine of the 
same dose to each group 6 months after the initial dose, which greatly increased the rAd5 
vaccine’s capabilities. The boosting vaccine induced a strong response regardless of pre-
existing Ad5 immunity, with GP-specific antibody titers escalating to GMTs of 6110 and 
11825 in the low- and high-dose participants respectively 28 days after the boost 
vaccination (Li et al., 2016). These titer values did slowly decrease to GMTs of 674.1 and 
856.8 by month 12, but the overall increase is still very noticeable in comparison to the 
day 168 values for prime vaccination (Li et al., 2016). The GP specific T-cell response, 
however, was not as strong; although both the low and high doses experienced an 
increased specific T-cell response after the boosting vaccination (23.3 and 95 
SFU/million PBMC respectively), the magnitude of the response was still lower than the 
values for day 28 after the initial vaccination (Li et al., 2016). It was also noted that the 
boost vaccination did not induce Ad5 immunity as strongly as the prime vaccination, as it 
only led to a small increase that swiftly diminished over 12 months (Li et al., 2016). 
Although a single dose of the rAd5 vaccine experienced limitations in its 
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immunogenicity, a boosting regimen can potentially rectify many of these problems, 
especially with regards to the anti-GP specific antibody response. 
While these results may be derived from a Phase 1 trial, the rAd5 vaccine has 
progressed to Phase 2 trials, a recent one having been conducted in a country severely 
damaged by the 2014-2016 Ebola outbreak. In Sierra Leone, 250 individuals were 
selected to receive a rAd5 dose of 1.6 x 1011 PU, while 125 individuals received a dose of 
8 x 1010 PU or placebo (Zhu et al., 2017). Solicited adverse reactions were somewhat 
frequent, with 53% of high-dose and 48% of low-dose participants experiencing at least 1 
reaction, although it should be noted that 43% of the placebo group also experienced 
these symptoms (Zhu et al., 2017). The high dose and low dose groups didn’t have a 
major difference in adverse symptoms, which manifested within 24 hours after 
vaccination and resolved themselves within 48 hours, although both groups had more 
local adverse reactions at the injection site than the placebo (Zhu et al., 2017). Pain was 
the most common local symptom of vaccination, while headache and fever were the most 
prevalent systemic reactions (Zhu et al., 2017). Unfortunately, unsolicited adverse 
reactions were also fairly prevalent, appearing in 59% of the high-dose participants and 
65% of the low-dose participants, although the placebo group also had a fairly high 
percentage (54%) of unsolicited manifestations, of which no specifics were provided 
(Zhu et al., 2017). Apart from the increased frequency of adverse effects, there were no 
serious concerns or severe adverse effects that were considered related to the vaccine 
(Zhu et al., 2017). Overall, the rAd5 vaccine proved to be relatively safe in the phase 2 
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trial; despite the increased frequency of adverse effects, most of the adverse effects 
themselves proved to be mild and ultimately inconsequential. 
While the rAd5 vaccine might be reactogenic, it also displayed a higher level of 
immunogenicity than in previous studies. A large majority of the vaccine recipients in 
both the high and low dose groups (both 96%) began expressing a GP-specific antibody 
response starting at day 14, which peaked at day 28 with GMTs of 2043.1 and 1471.8, in 
comparison to the placebo GMT of 6.0-6.8 (Zhu et al., 2017). Although dose did play a 
role in the strength of the antibody response, in this study it only contributed to a 
temporarily higher GMT for the high-dose group over the low-dose group at day 28, and 
did not cause any significant differences before or after (Zhu et al., 2017). Unlike other 
studies, both the low dose and high dose of the vaccine were able to elicit strong antibody 
responses regardless of any pre-existing immunity to Ad5, although for both doses the 
strength of the response rapidly decreased to GMTs of 223.3 for the low dose and 254.2 
for the high dose by day 168 (Zhu et al., 2017). On the other hand, the GMTs for Ad5 
neutralizing antibodies increased drastically after vaccination for both doses by day 14, 
and even though they decreased afterwards they still remained 3-5x higher at day 168 
than they did originally (Zhu et al., 2017). The immunogenic profile of the rAd5 vaccine 
was greatly improved in terms of antibody reaction, especially since it was able to 
seemingly overcome the limitations of pre-existing Ad5 immunity. However, the Phase 2 
trial used higher doses than previous studies to achieve these results, and both the 
weakened GP-specific antibody response and increased presence of Ad5 neutralizing 
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antibodies by day 168 do not support the vaccine’s ability to provide long-term protection 
against Ebola in humans. 
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DISCUSSION 
 The Ebola outbreak of 2014-2016 has firmly solidified the disease’s role as one of 
the most devastating global health threats in the modern era. The first appearance of 
Ebola in the U.S. in 2014 demonstrated that the virus could spread beyond the boundaries 
of Africa, and as a result, vaccine development for Ebola has become a priority for the 
world (Wu et al., 2015). Three vaccines based off of different viruses: chAd3, rVSV, and 
rAd5, have risen up to the forefront as vaccine candidates especially after the Ebola 
outbreak. Each of the vaccines displays a strong safety and immunogenicity profile, 
which has garnered additional interest in them for clinical trials. However, they each also 
possess weaknesses that can limit their overall functionality and usability. 
  The chAd3 vaccine’s flaws are less pronounced than for the other vaccines. Its 
safety profile could be considered the strongest out of the three vaccines, since adverse 
effects in trials occurred with the least frequency and there were no major events that 
could jeopardize the use of the vaccine in human trials. However, the vaccine by itself is 
limited in its ability to maintain a strong long-term immunogenic response, as after the 
initial peak at 28 days the antibody titers for the chAd3 vaccine decreased by 6 months in 
the clinical trials. The chAd3 vaccine appears to reach its full potential if it is boosted 
with MVA, which not only increased the strength of the immunogenic response at its 
peak but also greatly improved the antibody titers for the vaccine by 180 days. While the 
prime-boost regimen may be an excellent vaccination strategy in theory, administering 
both the chAd3 prime immunization and MVA boost in an area affected by the Ebola 
outbreak may be more cumbersome than a vaccination that can provide similar 
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immunogenic benefits with a single dose. The chAd3 vaccine’s efficacy has also not been 
tested against Ebola directly, so the immunogenic characteristics of the vaccine are 
defined largely through antibody and T-cell responses only. 
 By contrast, the rVSV vaccine has significantly different strengths and 
weaknesses compared to the other potential Ebola vaccines. Out of the three vaccines, the 
rVSV vaccine studies raise the greatest safety concerns. Not only does this vaccine have 
the greatest chance of eliciting an adverse reaction, but it is also the only vaccine to 
induce a serious (though not severe) adverse response in the form of arthritis in a non-
negligible number of patients, which raised enough concern to require a “study hold” 
during the Phase 1/Phase 2 Trial in Geneva. However, the rVSV vaccine does have some 
important advantages that the other candidate vaccines lack, which may be great enough 
to overcome its flaws. In addition to consistently displaying a strong immunogenic 
response through anti-GP antibodies that can provide both short and long-term protection, 
the rVSV vaccine is the only vaccine that has displayed efficacy against Ebola directly 
(Falzarano, 2015). Through the phase 3 trials in Guinea, an area that was afflicted by the 
Ebola outbreak of 2014-2016, the vaccine demonstrated a high degree of efficacy in the 
ring vaccination trial, able not only to protect against Ebola directly but also to do so in a 
large population setting with a much larger sample size than previous studies. It should 
also be noted that unlike the other vaccines, the WHO has taken a vested interest in the 
rVSV vaccine; the organization has played a role in both the Geneva and Guinea trials. 
The rVSV vaccine’s higher degree of reactogenicity is balanced out by its very strong 
52 
 
immunogenicity profile, and these significant advantages make it one of the most 
promising options for an Ebola vaccine candidate. 
 Out of the three vaccines, the rAd5 vaccine is arguably the least effective vaccine 
candidate. Its safety profile shows frequent manifestation of adverse effects, although 
unlike the rVSV vaccine these effects are mostly mild in nature and there are no unique 
or noteworthy adverse effects such as arthritis that have been strongly related to the 
vaccine. However, its greatest weakness is a pre-existing immunity to Ad5 in the form of 
neutralizing antibodies, which has significantly reduced the overall immunogenicity of 
the vaccine. The presence of pre-existing immunity has played a significant role in 
reducing both the response rate and magnitude of a disease, making it less consistent than 
the other two vaccine candidates. This problem is exacerbated by the high prevalence of 
Ad5 neutralizing antibodies in the human population, especially in African countries that 
are close to the countries afflicted by the outbreak. Consequently, the vaccine may not 
even function properly in the locations where it might be needed the most. These 
problems may possibly be mitigated by a homologous boosting regimen; however, the 
study that utilized this method required a 6 month difference between the priming and 
boosting immunizations, a method that may be impractical in the setting of an Ebola 
outbreak where strong and fast immune responses are paramount. Finally, the rAd5 
vaccine has a similar deficiency to the chAd3 vaccine in that it has not been directly 
tested against Ebola and must rely on antibody and T-cell responses to measure efficacy. 
 While the chAd3, rVSV, and rAd5 all display safety and immunogenicity profiles 
that are appropriate as vaccine candidates for Ebola virus disease, the rVSV vaccine 
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overall is the most viable. Although the high frequency of adverse symptoms and the 
prevalence of arthritis is problematic, the symptoms and lethality of Ebola are far more 
dangerous than any adverse effect caused by the rVSV vaccine, and successful protection 
against Ebola as a benefit greatly outweighs the risks caused by the vaccine. The rVSV 
vaccine also has the most robust immunogenicity profile and is farther along the process 
of vaccine development than the other two candidates, which has been highlighted by a 
phase 3 trial that has confirmed its effectiveness against Ebola directly. Although chAd3 
boosted with MVA is an alternate possibility that can provide short and long-term 
protection against Ebola without the frequency of adverse symptoms, rVSV as a stand-
alone vaccine has the greatest merit against a virus that has caused one of the most 
dangerous health crises of this decade. 
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